Theravance Biopharma, Inc.
TBPH
$8.40
$0.010.12%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.77% | 7.49% | 3.69% | 39.22% | 19.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.77% | 7.49% | 3.69% | 39.22% | 19.91% |
| Cost of Revenue | 13.71% | 11.51% | 5.61% | -38.46% | -45.84% |
| Gross Profit | 0.53% | 2.95% | -0.51% | 233.21% | 1,423.61% |
| SG&A Expenses | 16.73% | 4.54% | -11.53% | -12.72% | -5.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.69% | 6.91% | -5.90% | -23.83% | -24.68% |
| Operating Income | -39.46% | -5.88% | 14.71% | 51.98% | 62.15% |
| Income Before Tax | -78.21% | -32.56% | -7.29% | 53.73% | 64.82% |
| Income Tax Expenses | 88.55% | 93.56% | -10.29% | 419.49% | 116,566.67% |
| Earnings from Continuing Operations | -82.46% | -41.88% | -5.65% | 47.19% | 40.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.46% | -41.88% | -5.65% | 47.19% | 17.87% |
| EBIT | -39.46% | -5.88% | 14.71% | 51.98% | 62.15% |
| EBITDA | -41.47% | -6.22% | 12.76% | 50.71% | 63.74% |
| EPS Basic | -82.87% | -51.49% | -22.86% | 31.17% | -11.96% |
| Normalized Basic EPS | -66.62% | -19.56% | -9.62% | 35.16% | 56.80% |
| EPS Diluted | -82.87% | -51.49% | -22.86% | 31.17% | -11.96% |
| Normalized Diluted EPS | -66.62% | -19.56% | -9.62% | 35.16% | 56.80% |
| Average Basic Shares Outstanding | -0.22% | -6.35% | -14.00% | -23.28% | -26.68% |
| Average Diluted Shares Outstanding | -0.22% | -6.35% | -14.00% | -23.28% | -26.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
